Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Granules IndiaBOM:532482 -0.48%81 Interest Coverage is 12.27 as of Jun. 2026, which is 1% below its 10-year median of 12.44. GuruFocus rates BOM:532482 with a GF Score™ of 81/100 and a GF Value™ of ₹637.97 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 688 Drug Manufacturers companies, Granules India ranks worse than 57.99% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Granules India's
Operating Income
for the
three
months ended in Jun. 2026 was ₹2,593 Mil. Granules India's Interest Expense for the
three
months ended in Jun. 2026 was ₹-211 Mil.
Granules India's interest coverage for the quarter that ended in Jun. 2026 was 12.27.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Granules India's Interest Coverage or its related term are showing as below:
BOM:532482'
s Interest Coverage Range Over the Past 10 Years
Min: 7.8 Med: 12.44 Max: 48.56
Current: 8.69
BOM:532482's Interest Coverage is ranked worse than 57.99% of 688
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs BOM:532482: 8.69
Granules India (BOM:532482) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Granules India Interest Coverage Related Terms
Granules India Interest Coverage Historical Data
* Premium members only.
The historical data trend for Granules India's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Granules India's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Granules India Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Granules India's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Granules India's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Granules India (BOM:532482) has a Interest Coverage of 12.27 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Granules India and its competitors. This is near median its historical median of 12.44. Over the past decade, Granules India's Interest Coverage has ranged from 7.80 to 48.56. According to the industry distribution chart, Granules India ranks #399 out of 688 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is Granules India's Interest Coverage too high?
Granules India's current Interest Coverage of 12.27 is near median its 10-year median of 12.44. Over the past 10 years, this metric has ranged from a low of 7.80 to a high of 48.56. The Drug Manufacturers industry median Interest Coverage is 12.77. Granules India's value of 12.27 is 3.9% below this industry median. Based on the distribution chart, Granules India ranks #399 out of 688 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Granules India has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Granules India's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Granules India ranks #399 out of 688 companies for Interest Coverage. This places Granules India in the lower half of its industry. The industry median Interest Coverage is 12.77. Granules India's value of 12.27 is 3.9% below this benchmark. Historically, Granules India's own Interest Coverage has ranged from 7.80 to 48.56 over the past decade. While the company's 10-year median is 12.44 vs. the industry median of 12.77, Granules India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Granules India's current Interest Coverage of 12.27 is 3.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Granules India and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Granules India's current Interest Coverage is 12.27, which is near median its own 10-year median of 12.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Granules India stock overvalued right now?
Based on GuruFocus' analysis, Granules India (BOM:532482) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹637.97, compared to a current price of ₹841.65 — trading 31.9% above its estimated fair value. The current Interest Coverage is 12.27, which is near median its 10-year median of 12.44 and 3.9% below the Drug Manufacturers industry median of 12.77. Granules India's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Granules India (BOM:532482), the current Interest Coverage is 12.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Granules India (BOM:532482) Overvalued in 2026?
Based on GuruFocus' analysis, Granules India stock appears to be overvalued.
The current stock price of ₹841.65 is trading 31.9% above its estimated GF Value™ of ₹637.97.
GuruFocus considers Granules India to be Significantly Overvalued.
Key valuation signals for BOM:532482:
Interest Coverage: 12.27 (near median its 10-year median of 12.44)
GF Value™: ₹637.97 vs. price of ₹841.65 (31.9% above fair value)
Industry Position: 3.9% below the Drug Manufacturers median (#399 of 688)
No single metric tells the full story. See the BOM:532482 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World. The company generates a majority of its revenue from its business outside India.
81GF Score
Get the complete analysis for BOM:532482
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532482 has been successfully added to your 
